ClinicalTrials.gg
CompletedNCT04046991Updated Oct 19, 2026Results posted

Treating Primary Progressive Aphasia (PPA) Using High-definition tDCS

A Phase 2 interventional study of high-definition transcranial direct current stimulation and modified constraint-induced language therapy in Primary Progressive Aphasia, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by University of Pennsylvania · Phase 2, Interventional, and Treatment

How we know

Updated Oct 19, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Aphasia, Primary Progressive with a site in United States — 20 open to participants now, 24 under way, none of them phase 3. Aphasia, Primary Progressive · United States.

Enrollment
12th of 43
76 · median 30
Started
2020
with 5 others
Phase 2
5 of 51
2 open now
Registered
19th of 51
by date
Lead sponsor
5 of 51
University of Pennsylvania

Among the 51 studies in Aphasia, Primary Progressive with a site in United States, this one is the 12th largest by enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2020, is one of 5 in phase 2, and was the 19th registered.

Aphasia, Primary Progressive

77 studies on the registry are indexed under Aphasia, Primary Progressive; 28 are open to participants now.

Browse Aphasia, Primary Progressive studies →

Open to participants now

20 of the 51 studies in Aphasia, Primary Progressive with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Aphasia, Primary Progressive studies recruiting now, 13 (54%) set no upper age limit and 1 (4%) stops at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Aphasia, Primary Progressive with a site in United States, or all of them as a file.
02

Study summary

This is a double-blind, sham-controlled, crossover study in which subjects with the non-fluent/agrammatic and logopenic variants of primary progressive aphasia (naPPA and lvPPA, respectively) will undergo language testing and structural and functional brain imaging before and after receiving 10 semi-consecutive daily sessions of real or sham high-definition transcranial direct current stimulation (HD-tDCS) paired with modified constraint-induced language therapy (mCILT). Language testing and brain imaging will be repeated immediately after completion of and 3 months following completion of treatment. The 3-month follow-up will be the primary endpoint. The investigators will examine changes in language performance induced by HD-tDCS + mCILT compared to sham HD-tDCS + mCILT. The investigators will also use network science to analyze brain imaging (fMRI) data to identify network properties associated with baseline PPA severity and tDCS-induced changes in performance. This study will combine knowledge gained from our behavioral, imaging, and network data in order to determine the relative degrees to which these properties predict whether persons with PPA will respond to intervention.

Read the detailed description

The central framework for the project is a double-blind, sham-controlled, crossover study in which subjects with the non-fluent/agrammatic and logopenic variants of primary progressive aphasia (naPPA and lvPPA, respectively) will undergo language testing and structural and functional brain imaging before and after receiving 10 semi-consecutive daily sessions of real or sham high definition transcranial direct current stimulation (HD-tDCS) paired with modified constraint-induced language therapy (mCILT). Language testing and brain imaging will be repeated immediately after completion of and 3 months following completion of treatment.

Subjects with naPPA and lvPPA will be randomized to one of two study arms: HD-tDCS+mCILT or sham stimulation+mCILT paired with pre- and post-stimulation imaging and behavioral measures. Equal numbers of subjects with naPPA and lvPPA will be randomized to the HD-tDCS + mCILT and sham + mCILT study arms. The study is double-blinded, in that neither the subject nor the study personnel administering HD-tDCS or sham stimulation will know which arm of the study the subject has been randomized into. Study coordinators will administer HD-tDCS by entering a pre-determined code that has been programmed into the device by another member of the study team. Data will be digitally audio-recorded and analyzed off-line, such that study team members performing data coding and analysis will likewise be blinded to the treatment condition of each subject.

Subject participation in this protocol will occur during 27 planned visits that will span approximately 8 months. The events of the study visits are described below:

VISIT 1:

a Informed consent and screening b. Baseline language assessment #1 c. Baseline MRI scanning

VISIT 2:

Baseline language assessment #2

VISITS 3-11:

HD-tDCS+mCILT OR sham stimulation+mCILT, depending on the study arm to which they had been randomized.

VISIT 12:

  1. Final session of HD-tDCS+mCILT or sham stimulation+mCILT
  2. Follow-up language assessment
  3. Follow-up MRI

VISIT 13:

6-Week follow-up language assessment

VISIT 14:

  1. 12-week follow-up language assessment
  2. 12-week follow-up MRI

**CROSSOVER**

VISIT 15:

Crossover baseline language assessment #2

VISITS 16-24:

HD-tDCS+mCILT or sham stimulation+mCILT

VISIT 25:

  1. 10th session of HD-tDCS+mCILT or sham stimulation+mCILT
  2. Follow-up language assessment
  3. Follow-up MRI

VISIT 26:

6 Week follow-up language assessment:

VISIT 27:

  1. 12-week follow-up language assessment
  2. 12-week follow-up MRI
03

Conditions studied

  • Primary Progressive Aphasia

Keywords

  • non-invasive brain stimulation
  • transcranial direct current stimulation (tDCS)
  • aphasia
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of aphasia attributable to nonfluent agrammatic PPA (naPPA) or logopenic variant PPA (lvPPA)
  2. High school education (or more)
  3. Must be able to understand the nature of the study, and give
  4. Native English speaker

Exclusion criteria

Exclusion Criteria:

  • Presence of additional neurological illness such as stroke or traumatic brain injury
  • Diagnosis of epilepsy or reoccurening seizures
  • Pacemaker or ICDs
  • Craniotomy or skull breech
  • Small vessel disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Active comparator
    HD-tDCS+mCILT

    Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of HD-tDCS for 20 minutes using a montage in which a central electrode (1.5mA) is placed over the left frontotemporal area and four surrounding cathodes (.375mA each). Subjects will participate in a modified constraint-induced language therapy.

    Device: high-definition transcranial direct current stimulation · Behavioral: modified constraint-induced language therapy

  • Sham comparator
    Sham+mCILT

    Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham for 20 minutes using a montage in which a central electrode is placed over the left frontotemporal area and four surrounding cathodes. Subjects will participate in a modified constraint-induced language therapy,

    Device: high-definition transcranial direct current stimulation · Behavioral: modified constraint-induced language therapy

Interventions

  • Devicehigh-definition transcranial direct current stimulation

    High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp. It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways. HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.

  • Behavioralmodified constraint-induced language therapy

    Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.

06

What researchers measure

Primary outcomes

  1. Change in Western Aphasia Battery Aphasia Quotient (WAB-AQ)

    The primary outcome measure will be the change in score on the WAB-AQ, a score assessing overall aphasia recovery. Scores can range from 0-100. 0-25 is very severe, 26-50 is severe, 51-75 is moderate, and 76-above is mild. A score of 93 or higher is considered recovered.

    Time frame: At baseline, immediately after 2 week intervention, 6 and 12 weeks post intervention for HD-tDCS+mCILT and Sham intervention periods.

07

Results

Posted Oct 19, 2026

Participant flow

Participants were recruited from March 2020 - October 2024 from the Hospital of the University of Pennsylvania and surrounding Philadelphia area medical centers.

Participant flow — Overall Study
MilestoneHD-tDCS+mCILT First, Then Sham + mCILTSham+mCILT First, Then HD-tDCS + mCILT
Started3032
Completed3031
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChange in Western Aphasia Battery Aphasia Quotient (WAB-AQ)

The primary outcome measure will be the change in score on the WAB-AQ, a score assessing overall aphasia recovery. Scores can range from 0-100. 0-25 is very severe, 26-50 is severe, 51-75 is moderate, and 76-above is mild. A score of 93 or higher is considered recovered.

Time frame:
At baseline, immediately after 2 week intervention, 6 and 12 weeks post intervention for HD-tDCS+mCILT and Sham intervention periods.
Reported as:
Mean · Scores on a scale
Change in Western Aphasia Battery Aphasia Quotient (WAB-AQ)
Scores on a scaleHD-tDCS+mCILT First, Then Sham + mCILTSham+mCILT First, Then HD-tDCS + mCILT
Baseline Hd-tdcs + Mcilt81.3 ± 12.4681.26 ± 11.99
0 weeks post-Hd-tdcs + Mcilt82.52 ± 11.5281.68 ± 11.56
6 weeks post-Hd-tdcs + Mcilt81.96 ± 11.9181.40 ± 11.68
12 weeks post-Hd-tdcs + Mcilt81.45 ± 12.4080.17 ± 12.92
Baseline Sham+mcilt81.45 ± 12.4079.99 ± 13.07
0 weeks post-Sham+mcilt81.88 ± 12.8982.04 ± 11.48
6 weeks post-Sham+mcilt82.60 ± 12.4882.16 ± 11.45
12 weeks post-Sham+mcilt80.55 ± 15.1780.43 ± 13.32

Adverse events

Collected over From baseline, adverse event data were collected over a period of time consisting of 36 weeks (12 weeks for arm 1 and 24 weeks for arm 2).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HD-tDCS + mCILT0/62 (0%)1/62 (1.6%)12/62 (19.4%)
Sham + mCILT0/62 (0%)3/62 (4.8%)10/62 (16.1%)
Most frequent serious events
Most frequent serious events
EventHD-tDCS + mCILTSham + mCILT
Cancer DiagnosisGeneral disorders0/621/62
Fall resulting in broken bone/fractureGeneral disorders1/621/62
Hernia + repairSurgical and medical procedures0/621/62
Most frequent other events
Showing 10 of 15
Most frequent other events
EventHD-tDCS + mCILTSham + mCILT
HeadacheGeneral disorders5/622/62
FallGeneral disorders3/620/62
Skin IrritationSkin and subcutaneous tissue disorders0/623/62
Jaw PainGeneral disorders1/620/62
Herniated discMusculoskeletal and connective tissue disorders1/620/62
MigraineNervous system disorders1/620/62
ShinglesInfections and infestations1/620/62
Viral InfectionInfections and infestations1/620/62
Skin biopsySkin and subcutaneous tissue disorders1/620/62
Head discomfortGeneral disorders0/621/62

Baseline characteristics

Age, Continuous
Age, Continuous(years)HD-tDCS + mCILT First, Then Sham + mCILTSham+mCILT First, Then HD-tDCS + mCILTTotal
Mean68.8 ± 8.2567.9 ± 7.6168.2 ± 7.95
Sex: Female, Male
Sex: Female, Male(Participants)HD-tDCS + mCILT First, Then Sham + mCILTSham+mCILT First, Then HD-tDCS + mCILTTotal
Female141529
Male161733
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HD-tDCS + mCILT First, Then Sham + mCILTSham+mCILT First, Then HD-tDCS + mCILTTotal
Hispanic or Latino011
Not Hispanic or Latino303161
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HD-tDCS + mCILT First, Then Sham + mCILTSham+mCILT First, Then HD-tDCS + mCILTTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White293261
More than one race000
Unknown or Not Reported000
Western Aphasia Battery (WAB-AQ) Score
Western Aphasia Battery (WAB-AQ) Score(scores on a scale)HD-tDCS + mCILT First, Then Sham + mCILTSham+mCILT First, Then HD-tDCS + mCILTTotal
Mean81.52 ± 12.1880.08 ± 12.6680.77 ± 12.45
08

Study locations

1 site
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Jun 2025, 58 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2019
First posted
Aug 6, 2019
StartActual
Aug 17, 2020
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Results first posted
Oct 19, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 19, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameChange in Western Aphasia Battery Aphasia Quotient (WAB-AQ)Baseline, 2 weeks, 6 weeks, 12 weeks, 14 weeks, 18 weeks, 24 weeks → At baseline, immediately after 2 week intervention, 6 and 12 weeks post intervention for HD-tDCS+mCILT and Sham intervention periods.
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Results posted
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameChange in Western Aphasia Battery Aphasia Quotient (WAB-AQ)Baseline, 2 weeks, 6 weeks, 12 weeks, 14 weeks, 18 weeks, 24 weeks → At baseline, immediately after 2 week intervention, 6 and 12 weeks post intervention for HD-tDCS+mCILT and Sham intervention periods.
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04046991
Responsible party
Sponsor
First posted
Aug 6, 2019
Start date
Aug 17, 2020
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Results posted
Oct 19, 2026
Last update
Oct 19, 2026

Study contacts

Roy H Hamilton, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion